Published September 13, 2006
| Supplemental Material + Accepted Version
Journal Article
Open
A Convergent and Enantioselective Synthesis of (+)-Amurensinine via Selective C−H and C−C Bond Insertion Reactions
Chicago
An error occurred while generating the citation.
Abstract
A convergent and enantioselective synthesis of the natural product amurensinine is described. The synthetic strategy takes advantage of mild and selective C−H and C−C bond insertion reactions, in addition to the palladium-catalyzed aerobic oxidative kinetic resolution recently developed in these laboratories.
Additional Information
© 2006 American Chemical Society. Received 20 July 2006. Published online 17 August 2006. Published in print 1 September 2006. The authors are grateful to the NIH-NIGMS (R01 GM65961-01), NDSEG (predoctoral fellowships to U.K.T. and D.C.E.), NSF (predoctoral fellowship to D.C.E.), A. P. Sloan Foundation, Research Corporation, Bristol-Myers Squibb, Amgen, Merck, Pfizer, Novartis, Lilly, Roche, Abbott, AstraZeneca, and Caltech for financial support.Attached Files
Accepted Version - nihms-63703.pdf
Supplemental Material - ja0651815si20060804_084023.pdf
Files
nihms-63703.pdf
Files
(1.7 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:51e1e85b7f7fe18d08d6f8ca81c40f4b
|
295.6 kB | Preview Download |
|
md5:1e0b910c85b41640c1ff6ad9a19b68be
|
1.4 MB | Preview Download |
Additional details
- PMCID
- PMC2529249
- Eprint ID
- 74438
- Resolver ID
- CaltechAUTHORS:20170221-152140812
- NIH
- R01GM65961-01
- National Defense Science and Engineering Graduate (NDSEG) Fellowship
- NSF Predoctoral Fellowship
- Alfred P. Sloan Foundation
- Research Corporation
- Bristol-Myers Squibb
- Amgen
- Merck
- Pfizer
- Novartis
- Lilly
- Roche
- Abbott
- AstraZeneca
- Caltech
- Created
-
2017-02-22Created from EPrint's datestamp field
- Updated
-
2021-11-11Created from EPrint's last_modified field